XML 92 R78.htm IDEA: XBRL DOCUMENT v3.22.1
Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)
1 Months Ended 12 Months Ended
Jun. 10, 2021
shares
Nov. 30, 2021
USD ($)
shares
Feb. 28, 2021
USD ($)
shares
Sep. 30, 2020
USD ($)
shares
Aug. 31, 2020
shares
Mar. 31, 2022
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
$ / shares
shares
Mar. 31, 2020
USD ($)
$ / shares
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Shares reserved for future issuance           144,601,515 278,819,076  
Exchange ratio of common stock           2.293698169    
Stock Options, Granted           14,968,952    
Shares Available for Grant, Exercised           5,808,526    
Share-based compensation terms of award           Options under the 2021 Plan have a contractual life of up to ten years. The exercise price of a stock option shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors.    
Weighted-average grant date fair values of options granted | $ / shares           $ 4.44 $ 3.02 $ 2.73
Intrinsic value of vested options exercised | $           $ 25,600 $ 47,600,000 $ 19,000.0
Weighted average period over which unrecognized compensation is expected to be recognized           2 years 9 months 18 days    
Unrecognized stock-based compensation expense | $           $ 104,100    
Stock-based compensation expense | $           57,933,000 86,696,000 41,058,000
Proceeds from stock options exercised | $           $ 16,998,000 $ 76,151,000 8,830,000
Common stock subject to repurchase           0 0  
Options Exercised           0 0  
Vesting Early Exercised Stock Options | $           $ 0 $ 91,046,000 16,962,000
Lemonaid Health, Inc. [Member]                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Weighted average period over which unrecognized compensation is expected to be recognized           3 years 7 months 6 days    
Common stock granted subject to vest   3,747,027            
Unrecognized stock-based compensation expense | $           $ 39,400,000    
Common stock granted subject to vest, Weighted average grant date fair value | $   $ 43,900,000            
Vesting peiod   4 years            
General and Administrative Expense [Member]                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Stock-based compensation expense | $     $ 40,400,000     22,242,000 $ 59,986,000 $ 18,932,000
General and Administrative Expense [Member] | Lemonaid Health, Inc. [Member]                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Stock-based compensation expense | $           $ 4,500,000    
Restricted Stock Units [Member]                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Weighted average period over which unrecognized compensation is expected to be recognized           3 years 6 months    
Unrecognized stock-based compensation expense | $           $ 96,000,000.0    
Early Exercise of Common Stock Options [Member] | CEO                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Stock Options, Granted         6,881,095      
Shares Available for Grant, Exercised       6,881,095     11,108,906  
Proceeds from stock options exercised | $       $ 34,700,000     $ 47,200,000  
Shares Vested     15,621,041          
2021 Incentive Equity Plan [Member]                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Shares reserved for future issuance 136,000,000              
Exchange ratio of common stock           2.293698169    
Shares Available for Grant, Beginning balance           22,839,019    
Common stock issued and outstanding, percentage           3.00%    
Exercise price of stock options as a percentage of fair value of shares           110.00%    
Share-based payment award, description           The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting in 2022, in an amount equal to (i) 22,839,019 shares of Class A common stock, (ii) 3.0% of the aggregate number of shares of Class A common stock and Class B common stock outstanding, or (iii) a lesser number of shares determined by the Company’s Board of Directors prior to the applicable January 1    
2021 Incentive Equity Plan [Member] | Lemonaid Health, Inc. [Member]                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Shares reserved for future issuance   2,990,386            
2021 Incentive Equity Plan [Member] | Stock Option Activity [Member]                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Percentage of total stock holding           10.00%    
2021 Incentive Equity Plan [Member] | Maximum [Member]                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Shares reserved for future issuance 136,000,000              
2021 Incentive Equity Plan [Member] | Minimum [Member]                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Exercise price of stock options as a percentage of fair value of shares           100.00%    
ESPP [Member]                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Shares reserved for future issuance 11,420,000              
Common stock issued and outstanding, percentage (1.00%)              
Potential annual increase in shares reserved for future issuance 5,000,000              
Number of shares issued           0    
Amount withheld | $           $ 600,000    
2006 Equity Incentive Plan | Performance Based Awards [Member]                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Stock Options, Granted           0    
Class B Common Stock [Member]                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Common stock subject to repurchase               8,739,945
Weighted Average Repurchase Price | $ / shares               $ 11.50
Class B Common Stock [Member] | CEO                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Shares Available for Grant, Exercised     11,029,071          
Proceeds from stock options exercised | $     $ 32,600,000